QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How PRAC Assesses a Safety Issue During an EMA Referral

Test your understanding of the concepts covered by How PRAC Assesses a Safety Issue During an EMA Referral.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An epidemiological study does not find a statistically clear association, but the event is severe and the study has limited power. What is the most defensible regulatory interpretation?

The study excludes a clinically important risk. The absence of statistical clarity must be interpreted in light of study power and the broader evidence; it does not automatically exclude the risk. The event should be treated as proven because it is severe. Only spontaneous reports should be considered from that point onward.

Question 2 of 10 What is the most appropriate interpretation of a PRAC request for additional data or clarification?

It necessarily proves that the MAH's original submission was deficient. It is part of the iterative scientific assessment and may address gaps, inconsistencies, subgroup questions or potential regulatory consequences. It means PRAC has already decided to restrict the product. It permits the MAH to replace the original evidence with unsupported opinion.

Question 3 of 10 A cluster of well-documented cases shows a consistent temporal relationship between exposure and an event. What is the most appropriate interpretation?

The cluster proves causality and establishes the required regulatory action. The cluster is irrelevant because case reports lack a complete exposure denominator. The cluster strengthens concern but should be interpreted alongside alternative causes, background incidence and other evidence. The cluster can be used only to estimate incidence precisely.

Question 4 of 10 What most appropriately distinguishes a PRAC safety-referral assessment from routine signal management?

It determines whether the original signal is statistically significant using spontaneous-report data only. It assesses a defined regulatory question within the referral's legal and procedural scope and determines the implications for benefit-risk and regulatory action. It focuses exclusively on drafting revised product information. It replaces all subsequent decision-making by CHMP, CMDh and the European Commission.

Question 5 of 10 Which statement correctly distinguishes a scientific conclusion from a regulatory recommendation?

They are identical because confirming a risk automatically specifies the regulatory measure. The scientific conclusion characterises what the evidence means, while the recommendation translates that conclusion into an action within the applicable legal framework. The regulatory recommendation is made before the evidence is interpreted. The scientific conclusion is limited to product-information wording.

Question 6 of 10 How should the marketing authorisation holder's submission be treated in the PRAC assessment?

It is the definitive interpretation because the MAH owns the relevant data. It is a separate commercial position that should not be integrated with regulatory evidence. It forms part of the evidence base and is evaluated alongside information from EMA, national authorities and other stakeholders. It may be considered only if it supports the rapporteur's preliminary conclusion.

Question 7 of 10 What is the proper role of an oral explanation by an MAH during an applicable referral procedure?

To substitute for a complete written evidence package. To negotiate the scientific conclusion directly with individual committee members. To clarify contested scientific issues and respond directly to concerns within the procedural framework, while maintaining evidentiary discipline. To present uncertainty as certainty in order to secure a favourable outcome.

Question 8 of 10 Why should the formal referral question be established before assembling and interpreting evidence?

Because only evidence submitted by the referring authority can be considered. Because the question defines the relevant scope and prevents an unfocused review of every aspect of the medicine's safety profile. Because the referral question determines which scientific conclusion PRAC must adopt. Because evidence collected before the referral is legally irrelevant.

Question 9 of 10 Which statement about the downstream pathway after PRAC is most accurate?

PRAC recommendations are always the final legally operative decisions. Article 20 and Article 31 procedures always proceed only to CMDh. The subsequent pathway depends on the legal basis and products involved; CHMP or CMDh may be relevant, and a legally operative decision may follow through the applicable route. The MAH decides whether the PRAC recommendation becomes legally effective.

Question 10 of 10 Which of the following is the best treatment of uncertainty in a scientific referral assessment?

Omit uncertainty from the conclusion to avoid weakening the regulatory recommendation. Treat uncertainty itself as evidence that the risk is large. Describe what is known, what can reasonably be inferred and what remains uncertain, including whether the uncertainty could affect the decision. Delay all regulatory action until every uncertainty has been resolved.

Knowledge Assessment: How PRAC Assesses a Safety Issue During an EMA Referral

Cookie Settings